arXiv:2507. 03209v2 Announce Type: replace-cross Abstract: The discovery of new ionizable lipids for efficient lipid nanoparticle (LNP)-mediated RNA delivery remains a major bottleneck in RNA therapeutics development.
By Asal Mehradfar, Mohammad Shahab Sepehri, Jose Miguel Hernandez-Lobato, Glen S. Kwon, Mahdi Soltanolkotabi, Salman Avestimehr, Morteza Rasoulianboroujeni
arXiv:2606. 05200v1 Announce Type: cross Abstract: Lipid nanoparticles (LNPs) are efficient delivery systems for negatively charged nucleic acids.
By Maria B{\aa}nkestad, Sandra Barman, Magnus R\"oding, Erik Kaunisto, Viktoriia Meklesh, Audrey Gallud, Marco Mendez, Marianna Yanez Arteta, Stefan Norberg, Ann Terry, Smita Chakraborty, Shun Yu, Jerk R\"onnols, Sepideh Pashami
arXiv:2608. 05761v1 Announce Type: new Abstract: The development of nanotherapeutics often involves extensive empirical optimization due to the sensitivity of nanoparticle properties, such as size and polydispersity index (PDI), to minor changes in process parameters.
By Kai Dahms, Eilien Heinrich, Jochen Schmid, Michael Bortz, Iryna Savych, Regina Bleul
ToxLens is a reproducible multi‑task graph‑learning framework designed for leakage‑aware, uncertainty‑calibrated prediction of 11 molecular toxicity endpoints, including Ames mutagenicity and hERG inhibition. The workflow integrates conservative chemical curation, sphere‑exclusion filtering, a leakage‑aware UMAP‑HDBSCAN split, parallel graph and global‑feature encoders with late concatenation, temperature‑scaled Monte Carlo dropout, conformal‑style prediction sets, applicability‑domain analysis, and SHAP‑guided toxicophore discovery with occlusion controls. On a leakage‑controlled test fold, a five‑seed soft‑voting ensemble achieved MCC 0.44, AUROC 0.83, and AUPRC 0.58, outperforming four ECFP4‑based shallow baselines across all endpoints.
By Magnus H. Str{\o}mme, Alex G. C. de S\'a, David B. Ascher
Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket.
arXiv:2607. 12349v1 Announce Type: new Abstract: Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design.
By Ruoxi Gao, Jiangweizhi Peng, Ziqi Chen, Frazier N. Baker, David C. Kombo, John L. Kane Jr., Andrew A. Scholte, Yi Li, Matthew J. LaMarche, Luigi I. Iconaru, Hans-Peter Biemann, Mingyi Hong, Xia Ning